Management of differentiated thyroid cancer of the follicular epithelium

References

• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.
   PubMed Web of Science ®Google Scholar
• Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Maréchaud R, Niccoli-Sire P, . Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133–9.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, .; American Thyroid Association Guidelines Taskforce. The American Thyroid Association Guidelines Taskforce Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.
   PubMed Web of Science ®Google Scholar
• Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81–9.
   PubMed Web of Science ®Google Scholar
• Lundgren CI, Hall P, Dickman PW, Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg. 2007;94:571–7.
   PubMed Web of Science ®Google Scholar
• Malterling RR, Andersson RE, Falkmer S, Falkmer U, Nilehn E, Jarhult J. Differentiated thyroid cancer in a Swedish county-long-term results and quality of life. Acta Oncologica. 2010;49:454–9.
   PubMed Web of Science ®Google Scholar
• Hay ID, McDougall R, Sisson JC. Perspective: The case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med. 2008;49: 1395–7.
   Web of Science ®Google Scholar
• Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, . Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol. 2006;91:926–32.
   PubMed Web of Science ®Google Scholar
• Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, . A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542–6.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer. AJCC cancer staging manual. 6th New York, NY, USA: Springer; 2002.
   Google Scholar
• Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106:524–31.
   PubMed Web of Science ®Google Scholar
• Pelttari H, Välimäki MJ, Löyttyniemi E, Schalin-Jäntti C. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol. 2010; 163:757–63.
   Google Scholar
• Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14:764–74.
   PubMedGoogle Scholar
• Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-Iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87:1499–501.
   PubMed Web of Science ®Google Scholar
• Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175–8.
   PubMed Web of Science ®Google Scholar
• Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20:135–46.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–57.
   PubMed Web of Science ®Google Scholar
• Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, . Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;9376–81.
   Google Scholar
• Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, . Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol. 2007;67:434–41.
   PubMedGoogle Scholar
• Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, . Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92: 82–7.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, . Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab. 2007; 92:2487–95.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, . Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.
   PubMed Web of Science ®Google Scholar
• Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008;22:955–69.
   PubMed Web of Science ®Google Scholar
• Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009;94:1493–9.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, .; for the Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.
   Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, . Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Onc. 2008;28:4708–13.
   Google Scholar
• Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, . A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18:317–23.
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, . Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714–9.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Needles BM, Cullen KJ, Wong S, Wade J, Ivy P, . Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol. 2008;26 (abstract 6025).
   Google Scholar